Cite
HARVARD Citation
Han, E. et al. (2022). Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial. Diabetes, obesity & metabolism. 24 (4), pp. 752-756. [Online].